Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)
ID: 347224Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347224

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-148.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB)," aimed at supporting research on the long-term cardiopulmonary effects following tuberculosis (TB) treatment. This initiative seeks applications for epidemiological and observational studies that investigate adverse outcomes and morbidity associated with post-TB lung disease, particularly in both adult and pediatric populations, with a focus on individuals affected by HIV. Understanding the implications of post-TB lung disease is crucial for improving healthcare strategies and patient management for TB survivors. Interested applicants can find more information and submission guidelines at the NIH website, with applications due by May 7, 2026. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-148-Full-Announcement.html
    PAR-23-148.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced a Notice of Funding Opportunity (NOFO) titled "Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB)." This initiative aims to fund research that explores the long-term cardiopulmonary effects of tuberculosis (TB) treatment, emphasizing studies on both adult and pediatric cohorts, particularly regarding adverse outcomes related to post-TB lung disease (PTLD). Research proposals should focus on understanding the epidemiology, clinical manifestations, and biological mechanisms of PTLD, with an emphasis on individuals affected by HIV. Eligible applicants include higher education institutions, nonprofits, and government agencies, among others. The funding period can extend up to five years, with no budget limitations provided they reflect the project's actual needs. Applications for this grant must adhere strictly to NIH submission guidelines and are due by scheduled deadlines, with a primary goal of reducing the burden of long-term morbidity from TB. Understanding PTLD's impact on healthcare can inform better patient management and treatment strategies, ultimately improving health outcomes for TB survivors.
    Similar Opportunities
    Halting Tuberculosis (TB) Transmission (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Halting Tuberculosis (TB) Transmission," aimed at understanding and addressing the critical drivers of TB transmission in high-burden settings. The initiative seeks to develop effective measurement methods and assess potential low-cost interventions to prevent TB transmission, with a particular focus on the role of asymptomatic TB and leveraging insights from COVID-19 research. A total of $6 million is anticipated for FY 2025 to fund 4-5 awards, with each application budget capped at $750,000 per year over a maximum project period of 5 years. Eligible applicants include a diverse range of organizations, and interested parties can find more information and submission details at the provided NIH link, with applications due by December 4, 2024.
    Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection," aimed at supporting research into the mechanisms of host cell death related to Mycobacterium tuberculosis (Mtb) and HIV co-infections. The initiative seeks to identify immune targets for the development of host-directed therapies by studying both inflammatory and non-inflammatory cell death pathways, emphasizing the need for multidisciplinary research teams that may include experts in HIV, TB, cell biology, and oncology. This grant does not have a funding cap, but proposals must align with project needs, and the maximum project period is five years. Interested applicants, including various educational and nonprofit institutions, must submit their applications by December 7, 2024, through Grants.gov, adhering to the NIH Grants Policy Statement. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Innovative Approaches for TB Prevention and Case Finding to END TB
    Active
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is forecasting a federal grant opportunity titled "Innovative Approaches for TB Prevention and Case Finding to END TB." This initiative aims to develop, implement, and evaluate innovative strategies for tuberculosis (TB) prevention and case finding, focusing on high-burden settings and vulnerable populations, including those living with HIV, children, and economically disadvantaged individuals. The total estimated program funding is $5 million, with an award ceiling of $1 million for up to two cooperative agreements, and applications are expected to be submitted electronically by February 27, 2025. Interested applicants can reach out to Hoang Dang at 404.639.8965 or via email at hdang@cdc.gov for further information.
    Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled the Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01), which invites researchers to apply for access to valuable biospecimens collected from an ongoing longitudinal study focused on tobacco use behaviors and health outcomes in the U.S. This initiative primarily provides urine, plasma, serum, and genomic DNA samples to support research relevant to tobacco regulations under the Family Smoking Prevention and Tobacco Control Act. The PATH Study, launched in 2011, plays a crucial role in advancing scientific understanding of tobacco use and its implications for public health. Applications will open on March 30, 2024, and close on October 31, 2026, with evaluations based on alignment with PATH objectives and the merit of proposed research. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" aimed at supporting research on infectious diseases in resource-constrained countries. This initiative encourages applications from organizations based in low- and lower-middle-income economies, as classified by the World Bank, and seeks innovative proposals addressing diseases such as HIV/AIDS, tuberculosis, and malaria, with a focus on enhancing local scientific capacity. The total funding available for fiscal year 2024 is approximately $1,360,000, with individual project budgets capped at $125,000 per year for a maximum of five years. Interested applicants can find more information and submission guidelines at the NIH website, with applications accepted until August 1, 2025.
    Promoting Innovative Research in Treponema pallidum Pathogenesis (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Promoting Innovative Research in Treponema pallidum Pathogenesis" (R21 Clinical Trial Not Allowed), aimed at supporting exploratory research to enhance understanding of the pathogenesis of Treponema pallidum, the bacterium responsible for syphilis. This initiative is particularly relevant given the rising rates of sexually transmitted infections (STIs) and the increase in congenital syphilis cases, emphasizing the need for innovative research techniques to lower barriers in this field. The total funding commitment for Fiscal Year 2025 is $2 million, with plans to award 4 to 6 grants, allowing applicants to request budgets up to $275,000 for projects lasting no more than two years. Interested applicants should submit their proposals by November 4, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS)," aimed at supporting multidisciplinary research teams investigating HIV pathogenesis and its associated comorbidities. The initiative seeks to foster collaboration among experts in HIV science, pathobiology, metabolism, and related fields to explore critical health issues such as gastrointestinal health, liver diseases, kidney function, and obesity in the context of HIV. With a total funding allocation of $2 million for 2-3 anticipated awards, applicants can request up to $500,000 per year for a maximum of five years, with proposals due by November 21, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)." This initiative aims to encourage research into the role of inflammasomes in the neuropathology associated with HIV infection and substance use disorders, particularly focusing on their impact on neurocognitive disorders and immune function. The program seeks to bridge knowledge gaps in treatment and research by exploring how inflammasome activation is influenced by HIV and substance use, with the goal of translating findings into clinical applications. A total funding amount of $2 million is available to support up to four grants, with a submission deadline of February 13, 2024. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research initiatives focused on HIV-associated non-communicable diseases (NCDs) at low- and middle-income country (LMIC) institutions through the R21 Clinical Trial Optional grant. This program aims to support locally relevant research that explores the relationship between HIV infection and the development of NCDs, enhance research capacity, and foster collaborative networks among researchers in LMICs and the U.S. The grant provides funding up to $275,000 over a two-year period, with a submission deadline of December 8, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.